info@oncologyventure.com

First Patient Dosed in Phase 2 Study of PARP/Tankyrase Inhibitor 2X-121 for Metastatic Breast Cancer

CAMBRIDGE, Mass. and HOERSHOLM, Denmark, June 26, 2018 — Oncology Venture US Inc., Oncology Venture AB (OV:ST) (“OV”) and Medical...

June 1, 2018, 4:09pm CDT: Oral Presentation of 2X-121 Abstract at ASCO 2018

Ruth Plummer, MD, PhD, FRCP, will present an abstract describing the first-in-human Phase 1 study of 2X-121, an investigational PARP 1/2...

Abstracts on Three Pipeline Products Selected for 2018 ASCO Clinical Meeting

  Phase 1 Study of PARP Inhibitor 2X-121 Selected as Oral Presentation June 1, 2018 Hoersholm, Denmark and Cambridge, MA...

2X Oncology Announces Validation of Drug Response Predictor (DRP) for its PARP Inhibitor 2X-121

— Developed DRP Successfully Identified Responders and Non-responders to Treatment with 2X-121 in 13-Patient Blinded Study —  Cambridge, MA – August...

Oncology Venture and Eisai Forge Exclusive Global License Agreement for Clinical Stage Oncology Drug PARP Inhibitor E7449 / 2X-121

2X Oncology to conduct Phase 2 Study of 2X-121 in metastatic breast cancer patients Hoersholm, Denmark, and Cambridge, MA, July...